Mechanistically, IL-32 has been demonstrated to promote changes in gastric cancer cell morphology, facilitating their migration, and to enhance their potential for invasiveness by upregulating the expression of matrix metalloproteinases (MMP)-2 and 9, VEGF-A, and IL-8 via HIF-1α activation [19]. This evidence concerns the gene VEGFA and gastric cancer.